POPULARITY
21 episodes with endometrial
15 episodes with endometrial
8 episodes with endometrial
6 episodes with endometrial
7 episodes with endometrial
5 episodes with endometrial
6 episodes with endometrial
6 episodes with endometrial
6 episodes with endometrial
In this conversation, Dr. Shawn Tassone discusses the complexities of postmenopausal bleeding, emphasizing the importance of understanding hormone health and the potential implications of bleeding in postmenopausal women. He outlines the diagnostic procedures, including ultrasounds and endometrial biopsies, and explains the significance of various results. Dr. Tassone also addresses the management of endometrial polyps and fibroids, the common occurrence of spotting during hormone replacement therapy, and encourages women to seek medical advice when experiencing unusual symptoms. The conversation aims to educate and empower women regarding their hormonal health and the importance of early detection of potential issues. Episode Highlights: Postmenopausal bleeding should always be investigated. Ultrasounds are crucial for assessing endometrial thickness. Endometrial biopsies can be life-saving tests. Spotting can be common when starting hormone therapy. Polyps are usually benign but can cause bleeding. Understanding hormone levels is key to managing symptoms. Cancers develop over time, not suddenly. Women should not fear hormone replacement therapy. Early detection of uterine cancer is possible and important. Consulting with a physician is essential for any unusual symptoms. Episode Resources: Dr. Shawn Tassone's Practice | https://www.drshawntassone.com Dr. Shawn Tassone's Book | The Hormone Balance Bible Dr. Shawn Tassone's Integrative Hormonal Mapping System | Hormone Archetype Quiz Thank you to our sponsor, Endurance Products Company! After over 25 years of practicing medicine, I'll be the first to tell you that not all supplements are created equal. But when I discovered Dihydroberberine SR, by Endurance Products Company, I was genuinely impressed. It's highly bioavailable and outperforms standard berberine at significantly lower doses. You can explore their offerings at endur.com. Not only is the science solid, but I love that Endurance Products Company is a family-run American company that has cared about doing things right since 1978. I've started recommending Dihydroberberine to my patients who struggle with blood sugar management, and the results speak for themselves. So much so, that I personally take this supplement for helping to support healthy blood sugar levels, heart health, and tap into how my body uses fats for energy As a special offer for my audience, Endurance Products Company is providing a 10% discount on your order! Simply use the code DRT10 at checkout when you visit endur.com. Medical Disclaimer This podcast and website represent the opinions of Dr. Shawn Tassone and his guests. The content here should not be taken as medical advice and is for informational purposes only. Because each person is so unique, please consult your health care professional for any medical questions.
Endometrial ablation has become a cornerstone procedure in the treatment of abnormal uterine bleeding, but is it the right solution for every patient that meets the indication? In this episode of the BackTable OBGYN Podcast, Dr. Ted Anderson from Vanderbilt University joins host Dr. Mark Hoffman to discuss the evolution of endometrial ablation and its contemporary utilization, including patient selection, technical considerations, and alternative treatments for abnormal uterine bleeding. --- SYNPOSIS Dr. Anderson begins by detailing the history of abnormal uterine bleeding alongside the evolution of the endometrial ablation techniques that have been used to treat it. Shifting focus to current day practice, he then shares his approach to endometrial ablation, covering patient selection and the technical aspects of his approach. Throughout the conversation, Dr. Anderson emphasizes the importance of how we define success in endometrial ablation, explaining that eumenorrhea (normal bleeding that no longer interferes with life events) is the goal, as opposed to the more traditional view that amenorrhea is the target outcome. The episode closes with a discussion on the role of alternative treatments, such as the Mirena IUD and hysterectomy for abnormal uterine bleeding. --- TIMESTAMPS 00:00 - Introduction 09:29 - History of Abnormal Uterine Bleeding and Endometrial Ablation 23:31 - Evolution of Endometrial Ablation Devices/Techniques 31:11 - Selecting the Right Patient for Ablation Success 34:38 - Post-Tubal Sterilization Ablation Syndrome 38:27 - The Role of IUDs in Managing AUB 44:07 - Reevaluating Endometrial Ablation Success Metrics 49:55 - Innovative Ablation Techniques: Cryoablation and Steam 51:48 - Adenomyosis and Fertility-Sparing Treatments 57:28 - Final Thoughts
Another interview with Voice No. 67 out of 100 for the Scars of Gold campaign and in this episode we have Mev sharing her story of Endometrial cancer at the age of 31.Mev's experience is a poignant reminder of why knowing the red flags of even rarer cancers is important. When Mev began having new and unexpected heavy and painful bleeding, a routine procedure to remove polyps actually identified early stages of Endometrial cancer. Initially managed with hormone therapy for 3 years Mev later went on to be diagnosed with ovarian cancer with it being unclear if this was a new primary or metastases from the endometrial cancer. Eventually Mev needed a full hysterectomy putting her into surgical menopause and living with Stage 4 cancer by the age of 37. Mev shares how her entire life has been taken out of her control and where she has found strength and support to process this diagnosis. We also talk about the wonderful support provided by the spotlight charity Victoria's Promise who provide support for women experiencing cancer.Thank you to Mev for sharing her story and raising awareness as part of our campaign. Scars of Gold is a health awareness campaign sharing the voices of 100 women facing their mortality at a young age with life changing or incurable health conditions, led by Dr Liz Murray and photographer Sammy Weston. Produced by the charity @mortalandstrong (No. 1209448)#podcast #podcastprevious #interview #mortalandstrong #scarsofgold #kintsugi #hope #pov #dr #drliz #drlizmurray #art #documentary #realvoices #breastcancer #cancer #mortal #womenshealth #healthmatters #healthadvocate #healthinequalities Hosted on Acast. See acast.com/privacy for more information.
Welcome back to today's Friday Review where I'll be breaking down the best of the week! I'll be sharing specifics on these topics: Weekly Podcast Recap Coros Pace 3 vs. Apple Watch (product review) Dostarlimab and Endometrial & Colorectal Cancer (research) For all the details tune in to today's Cabral Concept 3290 – Enjoy the show and let me know what you thought! - - - For Everything Mentioned In Today's Show: StephenCabral.com/3290 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!
Dr. Martin answers questions sent in by our listeners. Some of today's topics include: Pneumobilia Bile salts Macular degeneration Cortisol & hot flashes Licorice root tea on Reset Urine albumin Peripheral neuropathy Numbness in left arm & leg Endometrial ablation
¿Cómo se realiza la preparación endometrial? ¿Qué es la coordinación de ciclos? En el episodio de hoy la Dra. Azul Torres
Vincent travels to the Karolinska Institute in Stockholm to meet up with Niklas Björkström and Joakim Dillner to review their research on the endometrial immune system, and the plan to eliminate cervical cancer in Sweden. Host: Vincent Racaniello Guests: Niklas Björkström and Joakim Dillner Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode MicrobeTV Discord Server Endometrial immune system variation (Sci Immunol) Immune defense in the womb (News from Karolinska) HPV vaccination and screening for elimination (Nat Comm) Cervical cancer elimination strategies (Int J Cancer) Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv Content in this podcast should not be construed as medical advice.
Today on The Egg Whisperer Show podcast, I'm honored to be sharing a conversation all about endometrial analysis. Originally hosted by Tiffany Stankewicz and Nasser Al Asmar of Igenomix / Vitrolife Group, this interview included Dr. Allison Rodgers and Dr. Aimee We did a deep dive on how endometrial analysis works, and the tools that are available for fertility patients to get a better understanding of what may be happening with their endometrial lining. We also talk about how endometrial receptivity testing can lead to better outcomes for patients. The truth is that up to 30% of women have pathogenic bacteria in their endometrial lining that can negatively affect an embryo's ability to implant, and the good news is that there are simple antibiotics that can improve the lining. Dr. Rodgers and I have both had a lot of experience using the tools that Igenomix has created to test the endometrium, and we have both found that they can improve a patient's chance for a successful pregnancy. They call the trio of tests “Endometrio” and it includes EMMA, ALICE, and ERA. These three tests do the following: ERA (Endometrial Receptivity Analysis) - The ERA test evaluates the stage of an endometrium to determine if a receptive or non-receptive genetic profile is present at the time of biopsy. EMMA (Endometrial Microbiome Metagenomic Analysis) - A screening test to evaluate the endometrium at the microbiological level. ALICE (Analysis of Infectious Chronic Endometritis) - ALICE detects the bacteria causing chronic endometritis to improve your patient's reproductive prognosis. Tune in to learn more about endometrial analysis and how these tests, and the science behind them, can give fertility patients more insights about their endometrium, implantation, and chances for pregnancy. Thank you for hosting, Tiffany and Nasser, and thank you for the great discussion, Allison! You can tune in to all of the discussions hosted by Igenomix at ASRM on YouTube. You can find Igenomix here. Do you have questions about IVF? Click here to join Dr. Aimee for The IVF Class. The next live class call is on Monday, November 21, 2024 at 4pm PST, where Dr. Aimee will explain Egg Freezing and there will be time to ask her your questions live on Zoom. Watch videos of Dr. Aimee answer Ask the Egg Whisperer Questions on YouTube. Sign up for The Egg Whisperer newsletter to get updates Dr. Aimee Eyvazzadeh is one of America's most well known fertility doctors. Her success rate at baby-making is what gives future parents hope when all hope is lost. She pioneered the TUSHY Method and BALLS Method to decrease your time to pregnancy. Learn more about the TUSHY Method and find a wealth of fertility resources at www.draimee.org.
In this episode, listen to Ana Oaknin, MD, PhD and Alexandra Leary, MD, PhD, share their clinical insights and takeaways on key updates and new data presented for ovarian, endometrial, and cervical cancer at the ESMO 2024 annual congress including:Phase III PRIMA/ENGOT-OV26/GOG-3012 Final OS Results: Niraparib as First-Line Maintenance in Advanced Ovarian CancerATHENA COMBO/GOG-3020/ENGOT-ov45: Rucaparib With or Without Nivolumab Maintenance in Newly Diagnosed Ovarian CancerPhase II PICCOLO Trial of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive Ovarian Cancer With High-FRα ExpressionPhase III KEYNOTE-B21/GOG-3053 Study of Adjuvant Chemotherapy With or Without Radiotherapy With or Without Pembrolizumab in Patients With Newly Diagnosed Endometrial Cancer or Carcinosarcoma After Curative Surgery With no Residual DiseasePhase III KEYNOTE-A18 Overall Survival Results: Pembrolizumab Plus Concurrent Chemoradiation in High-Risk Locally Advanced Cervical Cancer Program faculty:Ana Oaknin, MD, PhDHead of Gynaecologic Cancer ProgrammeDepartment of Medical OncologyVall d' Hebron University HospitalVall d'Hebron Institute of Oncology Barcelona, SpainAlexandra Leary, MD, PhDCo-Director, Department of Medical OncologyMedical Oncologist, GynecologyTeam Leader, Gynecologic Translational Research Lab, Institut Gustave RoussyParis, FranceResources:To download the slides associated with this podcast discussion, please visit the program page.
In today's episode, we discuss the use of hormone replacement therapy (HRT) and local oestrogen in all types of gynaecological cancer patients. Many women after ovarian, womb, cervical, vulval or vaginal cancers feel that they are left out of the conversation and research as so much emphasis is on the breast cancer community. So, here we are with a laser focus on menopause after gynae cancers and we hope this episode is helpful. We are joined by Mr. Vikram Talaulikar, an associate specialist at the reproductive medicine unit in University College London Hospitals NHS Foundation Trust and hon. associate professor at University College London. He explains that menopause after gynaecological cancer treatment is more challenging because it occurs suddenly and the symptoms are often more severe and persistent. We discuss the data and safety for the use of HRT and local oestrogen for:1) Ovarian cancer2) Endometrial cancer3) Cervical cancer4) Vaginal + Vulval cancerEpisode Highlights:00:00 Intro.13:05 HRT now considered for more cancer patients.14:04 HRT generally safe for most ovarian tumours.19:58 Prefer HRT after 12-24 months post-treatment.22:09 Cervical cancer: treatment options hinge on type.30:24 Post-surgery, vaginal oestrogen often necessary; discussions important.33:32 Research non-hormonal treatments before using vaginal oestrogen.38:39 Ideally see a menopause specialist early after cancer diagnosis.42:34 Sarcomas contraindicate hormone use.44:50 Holistic menopause care includes non-hormonal and local treatments.49:18 Discuss options with GP, oncologist, or nurse specialist.Connect with us:For more information and resources visit our website: www.menopauseandcancer.org Or follow us on Instagram @menopause_and_cancerJoin our Facebook group: www.facebook.com/groups/menopauseandcancerchathub A big thanks to our trusted sponsor, The Better Menopause. I'm excited to share their amazing product, The Better Gut with you. Most women don't realize that gut health and menopause symptoms are intrinsically linked—keeping your gut happy is the foundation for overall health, through all stages of life. The Better Gut is a daily capsule packed with a unique, science-backed probiotic blend designed to survive stomach acid, reach your gut alive and help improve symptoms such as bloating, hot flushes and anxiety. Go check them out - The Better Gut is a big help for many https://thebettermenopause.com/products/better-gut?selling_plan=690396627248
In this episode, we hear the remarkable story of Wenora Johnson, a three-time cancer survivor who faced the challenges of job loss, single motherhood, and pursuing an education, all while navigating her diagnoses. Wenora shares her experiences with warmth, humor, and wisdom, offering valuable insights for anyone facing adversity. We delve into the cultural taboos surrounding cancer in her community, the critical role genetics played in her health journey, and why involving loved ones in our health decisions is so essential. Wenora's story goes beyond survival; it's about how she turned her experience into a passion for patient advocacy, making a lasting impact in the cancer community. Key Highlights: 1. Given the significant role genetics play as a risk factor for cancer, it is important to keep your family and loved ones informed. 2. Give yourself grace; you don't have to become a patient advocate fighting for systemic change. It's perfectly okay if your focus is simply on getting through today. 3. Having a supportive healthcare team that genuinely wants to see you succeed is crucial—not only for the effort they'll put forth but also for inspiring you to stay healthy and proactive in your treatment. Feeling lost in your cancer experience? We've created interactive, disease-specific maps to help you see all the paths you might face. Launching this Fall! Sign up for access here. About our guest: Wenora Johnson is a three-time cancer survivor (Colorectal, Endometrial and Basel Cell Carcinoma), Volunteer Research/Patient Advocate and Navy Veteran. As a volunteer with various organizations, she shares her understanding of policy; research; genetic testing; hereditary cancer; patient engagement and clinical trials with patients and the healthcare community. Being a Lynch Syndrome patient, Wenora advocates for genetic testing and awareness. She serves on various panels and review boards to provide extensive feedback on her role as a patient and research advocate with organizations such as CAP (College of American Pathologist); Clinical Trials Curator for Fight CRC; FORCE (Facing Our Risk of Cancer Empowered) Research Advocate, Peer Navigator and Board Member; a Consumer Reviewer for the DoD Peer Reviewed Cancer Research Program; a PCORI Ambassador and Clinical Trials Panel Member; IRB for local community hospital; NRG Oncology Patient Advocate Committee Member and the AACR Scientist~Survivor Program - presenting a poster on financial toxicities and disparities among minority patients; Center for Genomic Interpretation (CGI) Acceptable Thresholds Committee Board Chair and an External Advisory Board Member for WCG Clinical Services. She has written various patient advocate blogs and participated as a guest speaker/panelist and serves as the Community Patient Advocate for the University of Chicago Comprehensive Cancer Center and the University of Chicago Cancer Center. Wenora works in administration in the greater Chicagoland area and enjoys reading and traveling with her family. Visit the Manta Cares website Disclaimer: All content and information provided in connection with Manta Cares is solely intended for informational and educational purposes only. This content and information is not intended to be a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
In this episode, we review the high-yield topic of Endometrial Polyp from the Reproductive section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Andrea Rosati. Mr. Rosati is a consultant at the Department of Gynecologic Oncology at Fondazione Policlinico Universitario Agostino Gemelli in Rome (Italy). He is currently attending a second level master "Gynecologic Oncology International Master" at the Catholic University of the Sacred Heart (Rome, Italy) accredited as a Subspecialty Fellowship by the European Society of Gynaecological Oncology. His main interest areas are gynecological cancer, surgical anatomy, and gynecologic oncology surgery. Highlights: This study evaluated the prevalence of concurrent endometrial cancer in patients with pre-operative diagnoses of atypical endometrial hyperplasia undergoing hysterectomy. Among 460 patients, 47.2% were found to have concurrent endometrial cancer. Sentinel lymph node biopsy provided prognostic and therapeutic information in 60.8% of cases. It also allowed for the adjustment of adjuvant therapy in 12.3% of high to intermediate-risk patients without increasing operative time or complication rates. The study suggests sentinel lymph node biopsy can provide valuable prognostic and therapeutic insights in managing atypical endometrial hyperplasia.
In this episode, listen to Floor J. Backes, MD, and Angeles Alvarez Secord, MD, MHSc, share their clinical insights and takeaways on new data presented for endometrial, ovarian, and cervical cancers presented at the 2024 annual meetings of the Society of Gynecologic Oncology and American Society of Clinical Oncology including:RUBY Part 1 Subgroup Analyses by MRR Status: Addition of dostarlimab to platinum-based therapy followed by dostarlimab maintenance in advanced endometrial cancerRUBY Part 2: Survival outcomes with addition of dostarlimab to platinum-based therapy followed by dostarlimab plus niraparib maintenance in advanced endometrial cancerSurvival Analyses From Phase III NRG GY018: Carboplatin plus paclitaxel with or without pembrolizumab as frontline treatment for patients with advanced endometrial cancerDUO-E: First-line therapy with carboplatin plus paclitaxel plus bevacizumab and durvalumab followed by maintenance with bevacizumab, durvalumab, and olaparib in newly diagnosed endometrial cancerLong-term Follow-up From SIENDO: PFS in TP53 wild-type and preliminary survival by molecular subgroups in patients with endometrial cancer and complete or partial response after ≥12 weeks of first line taxane/carboplatinSubgroup Analyses From the Randomized Phase III MIRASOL: Mirvetuximab soravtansine vs investigator's choice of chemotherapy in FR
To have your question featured in a future video, please email: questions@drmdc.health
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RZJ865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 27, 2025.Navigating Recent Advances in Endometrial Carcinoma Treatment: Expert Guidance to Unleash the Power of Immunotherapy and Other Emerging Therapeutic Regimens In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RZJ865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 27, 2025.Navigating Recent Advances in Endometrial Carcinoma Treatment: Expert Guidance to Unleash the Power of Immunotherapy and Other Emerging Therapeutic Regimens In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RZJ865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 27, 2025.Navigating Recent Advances in Endometrial Carcinoma Treatment: Expert Guidance to Unleash the Power of Immunotherapy and Other Emerging Therapeutic Regimens In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RZJ865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 27, 2025.Navigating Recent Advances in Endometrial Carcinoma Treatment: Expert Guidance to Unleash the Power of Immunotherapy and Other Emerging Therapeutic Regimens In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RZJ865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 27, 2025.Navigating Recent Advances in Endometrial Carcinoma Treatment: Expert Guidance to Unleash the Power of Immunotherapy and Other Emerging Therapeutic Regimens In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RZJ865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 27, 2025.Navigating Recent Advances in Endometrial Carcinoma Treatment: Expert Guidance to Unleash the Power of Immunotherapy and Other Emerging Therapeutic Regimens In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.
I think it takes a lot of courage for anyone to share the challenges, traumas and uncertainties in their life with the rest of the world. What Tennille and Lydia are doing with their mother-daughter memoir, '(Un)Remarkable: How Cancer and Depression Intertwined Our Stories of Grief and Hope' is worth celebrating. The first time I met Tennille Corbett was in May of 2023 in the Tommy Douglas Collegiate theatre in Saskatoon. She was in the audience, sitting in a special wheelchair called a Broda Chair, about to watch her daughter, Lydia, perform in the school's production of Mamma Mia. Lydia was the lead in the musical and there was no way Tennille was going to miss this show.A few weeks earlier, Tennille had been diagnosed with Stage 4 Endometrial cancer and quickly had surgery. The diagnosis sent her on a life-changing path many in our community have travelled in regards to cancer. It forced Tennille to take a leave from work as she underwent treatment, which meant she had a lot more time with her husband, Shane, her son Aidan, their dog, Remmy, and of course, Lydia. What was she going to do with all of this time?Write a book of course! This wouldn't be just any type of book. Tennille wanted to write a mother-daughter memoir as she noticed there were very few book like this on the market. I spoke with Tennille and Lydia in the attic of their home which has been converted into a beautiful space where Tennille writes and soon will be starting her own podcast. I really wanted to know how they were able to make this book happen and so we drill down pretty deep into the process. It's through this process that you will discover how hard but rewarding writing this book was for Tennille and Lydia. This is the Season Six finale of the podcast and I want to thank you for your continued support of all things YXE Underground. Whether you're listening to and sharing episodes, buying shirts and dog bandanas to raise money for local charities, or leaving reviews of episodes, your support means so much to me. I think we've managed to created a really vibrant little community around this podcast and that's just amazing in my opinion...so thank you!!I will have a few bonus episodes dropping throughout the summer but mostly I'll be gathering interviews for next season. As always, if you know of someone or perhaps an organization, which is doing great things in our community but is flying under the radar, let me know. Send me an email: ericandersonyxe@gmail.com or reach out through social media or my website.Have a wonderful summer and we'll talk soon!Cheers...Eric Host, Producer, Editor: Eric AndersonTheme Music: Andrew DicksonWebsite: https://www.yxeunderground.comRecorded: On Treaty 6 Territory and the traditional homeland of the Metis
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/ZPE865. CME/CPE/IPCE credit will be available until May 27, 2025.A Pharmacist's Take on Navigating the Expanding Therapeutic Landscape for Endometrial and Cervical Cancers: Insights on Coordinating and Delivering Effective Modern Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/ZPE865. CME/CPE/IPCE credit will be available until May 27, 2025.A Pharmacist's Take on Navigating the Expanding Therapeutic Landscape for Endometrial and Cervical Cancers: Insights on Coordinating and Delivering Effective Modern Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/ZPE865. CME/CPE/IPCE credit will be available until May 27, 2025.A Pharmacist's Take on Navigating the Expanding Therapeutic Landscape for Endometrial and Cervical Cancers: Insights on Coordinating and Delivering Effective Modern Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/ZPE865. CME/CPE/IPCE credit will be available until May 27, 2025.A Pharmacist's Take on Navigating the Expanding Therapeutic Landscape for Endometrial and Cervical Cancers: Insights on Coordinating and Delivering Effective Modern Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/ZPE865. CME/CPE/IPCE credit will be available until May 27, 2025.A Pharmacist's Take on Navigating the Expanding Therapeutic Landscape for Endometrial and Cervical Cancers: Insights on Coordinating and Delivering Effective Modern Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.
Answering your latest hormone and PCOS related questions: Relief against hirsutism Anti-androgenic therapies Endometrial hyperplasia with PCOS Moon cycling and cycle syncing your food Got a question you want me to answer next? Email me at info@laurence-annez.com LINKS MENTIONED: My 1:1 Hormone Program Fem Harmony https://laurence-annez.my.canva.site/ MASTERCLASS Mind Body alignment for the Feminine https://unique-builder-662.ck.page/603d5fcb50 Cycle Synced PCOS Recipe Bundle https://laurence-s-school-8369.thinkific.com/courses/cycle-synced-pcos-friendly-recipes PCOS Breakthrough Course https://laurence-s-school-8369.thinkific.com/courses/pcos-breakthrough PCOS holistic support group https://www.facebook.com/groups/183220068951436/ Tinkle Razors https://tinkleyourface.com/ BLOG: What to do about androgens if you have PCOS https://www.laurence-annez.com/health-wellness/androgens?rq=androgens CONNECT WITH LAURENCE: Follow me at @laurence.annez on Instagram for more updates and inspiring content. . SUPPORT THE SHOW: Help me reach more people by subscribing, rating, and reviewing on Apple Podcasts. I hope you loved this episode! If you did, take a screenshot, share to your IG stories and tag me @laurence.annez so I can share you!
The frequency of hematospermia in transgender women is unknown, indicating a gap in current medical understanding. Join medical experts Tamar Reisman, MD, Clinical Endocrinologist at New York Presbyterian Weill Cornell Medical Center, and Sina Jasim, MD, MPH, ACCR Editor-in-Chief and Associate Professor of Medicine at Washington University School of Medicine, as they delve into a groundbreaking clinical case report titled "Hematospermia in a Transgender Woman with Evidence for Endometrial Tissue in the Prostate." Tune in as they discuss the highlights of the case, when to screen for endometriosis or ectopic Müllerian epithelial tissue growth in transgender women undergoing feminizing gender-affirming hormone therapy, and how to address challenges and barriers to patient care. View the full report in the Jan. 2024 issue of ACCR at https://doi.org/10.1016/j.aace.2024.01.006.
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Ana Luzarraga to discuss molecular profiles as predictors of endometrial recurrence. Dr. Luzarraga is a Gynecologic Oncologist currently working in the Vall d'Hebron University Hospital in Barcelona, Spain. She has completed her two years ESGO fellowship in 2023 and is currently finishing her PhD programme about molecular profile in endometrial cancer. Highlights: Molecular subgroups of endometrial cancer present distinctive recurrence patterns: p53-abn tumors relapse mostly with peritoneal and distant disease and NSMP tumors at distance. Molecular profile is a stronger independent predictor for vaginal, peritoneal, and distant recurrence than classic histologic factors. P53-abn is the sole independent predictor of peritoneal relapse. P53-abn and NSMP are independent predictors of distant recurrence.
Doctors James Ferriss, Linda Duska, and Jayanthi Lea discuss the promise and the challenges of targeting the immune system with immune checkpoint inhibitors, or ICIs, in cervical and endometrial cancers. They also examine emerging data that support the use of ICIs in recurrent cervical cancer, the potential for curing some patients with advanced endometrial cancer, and molecular factors that make cervical cancer a good target for immunotherapy. TRANSCRIPT Dr. James Stuart Ferriss: Hello, and welcome to the ASCO Daily News Podcast. I'm Dr. James Stuart Ferriss, your guest host of the ASCO Daily News Podcast today. I'm an associate professor of gynecology and obstetrics and the Gynecologic Oncology Fellowship Program Director at Johns Hopkins Medicine. In today's episode, we'll be discussing the use of immunotherapy in cervical and endometrial cancers to advance the treatment of these malignancies. I'm delighted to be joined by two acclaimed experts in this space, Dr. Linda Duska and Dr. Jaya Lea. Dr. Duska is a professor of obstetrics and gynecology and serves as the associate dean for clinical research at the University of Virginia School of Medicine. Dr. Lea is a professor of obstetrics and gynecology and chief of gynecologic oncology at the University of Texas Southwestern Medical Center. Our full disclosures are available in the transcript of this episode, and disclosures related to all episodes of the podcast are available at asco.org/DNpod. Drs. Duska and Dr. Lea, it's great to have you on the podcast today. Dr. Linda Duska: Thanks, Dr. Ferriss. Dr. Jayanthi Lea: Thanks, Dr. Ferriss. Dr. James Stuart Ferriss: So, let's get started. In recent years, we've had a revolution in the treatment of advanced endometrial and cervical cancers with improved outcomes for patients treated with immunotherapy. And when we say immunotherapy, we're specifically talking about immune checkpoint inhibitors today. A few of these agents have actually been approved in the United States for the management of these diseases. In our discussion, I'd like to review the promise and challenges of targeting the immune system in patients with advanced endometrial and cervical cancers, as well as review the most recent evidence we have in these spaces. Let's start with cervix. We've had a lot of improvements in outcomes here, Dr. Lea, and with cervical cancer, we've seen improved overall survival with the incorporation of immunotherapy along with chemotherapy and anti-angiogenic therapy for advanced and recurrent disease. Can you remind us why cervical cancer is a good target for immunotherapy? Dr. Jayanthi Lea: Yes, Dr. Ferriss. Immunotherapy for cervical cancer is supported by several molecular factors. And I think first and foremost, it's so important to remember that the majority of cervical cancers are HPV-positive. And HPV-positive cancers can induce a high level of inflammation, but this high level of inflammation actually contributes to evasion of immune surveillance. What it also does is that it's responsible for the induction of PD-L1. And we've seen several studies that have shown that cervical cancers express PD-L1 anywhere from 50 to 90 percent of cases. Other pertinent factors to consider are that cervical cancer can be considered a tumor with a high tumor mutational burden. So, the number of somatic mutations that we see in the DNA can be considered as a proxy for neoantigens. And so the higher the level of neoantigens, the more immunogenic the tumor. And then lastly, about 1 in 10 cervical cancers present with microsatellite instability, which is an already established key biomarker for the response team in care. Dr. James Stuart Ferriss: So, thinking about targeting PD-L1, what clinical evidence do we have that supports the use of immune checkpoint inhibitors in recurrent cervical cancer? Dr. Jayanthi Lea: We now have several studies that have shown a benefit for immune checkpoint inhibitors. For example, KEYNOTE-158 was a phase 2 basket [trial] that investigated the antitumor activity of pembrolizumab, which is a PD-1 inhibitor, in multiple cancer types. And specifically for patients with previously treated advanced cervical cancer, we were able to see an overall response rate of about 15% in those patients who had PD-L1 positive. And similarly, the EMPOWER CERVICAL-1 study, which was a phase 3 randomized trial that investigated the efficacy of cemiplimab, which is another PD-1 inhibitor, versus investigator's choice of single agent chemotherapy, showed a significant difference in median overall survival and progression-free survival in the cemiplimab group. There are several other studies that have investigated the efficacy of PD-1 or PD-L1 inhibitors in cervical cancer. One specific PD-1 inhibitor is nivolumab. In CHECKMATE-358, nivolumab was associated with an overall response rate of 26% in women who had recurrent/metastatic cervical cancer. Dr. James Stuart Ferriss: Dr. Duska, do you have any thoughts? Dr. Linda Duska: I'm really interested in PD-L1 as a biomarker because in the KEYNOTE-A18 study, which we're going to get to, 95% of patients were PD-L1 positive by CPS, which is the scoring system that we use in cervix cancer. And some of the studies that you already mentioned, including BEATcc, which we're also going to talk about, reported results where PD-L1 wasn't even considered. And so it begs the question, since PD-L1 is actually – again, depending on when in the course of disease you look at it, but more recent studies suggest 95% of cervical cancers express PD-L1, and – agnostic is the word I was looking for – it seems at least in BEATcc and similar trials that PD-L1 is agnostic, but I wonder if PD-L1 is really a good biomarker for response to checkpoint inhibitor therapy and I wonder what your thoughts are. Dr. Jayanthi Lea: I think that's an excellent question. To your point, that's correct that we saw in KETYNOTE-A18 that more than 90% of the patients had PD-L1 positivity and the result is sort of generalizable to all comers. That's still a matter of debate as to how we see PD-L1 as a biomarker to incorporate checkpoint inhibitors in the treatment of patients. Dr. James Stuart Ferriss: So, let's talk about the use of immune checkpoint inhibitors in the frontline setting. Until recently, we haven't seen much improvement in overall survival since the introduction of anti-angiogenic therapy to the chemotherapy backbone, and that was in GOG 240. Let's talk about the changes that have recently occurred in this space. Dr. Jayanthi Lea: So, we've had some very exciting data specifically from initially KEYNOTE-826 and its primary metastatic or first line salvage settings. So, KEYNOTE-826, which was a phase 3 randomized, controlled trial was very practice-changing for us because it showed that incorporation of pembrolizumab to the first-line treatment of patients with metastatic or recurrent cervical cancer, really changed the landscape for treatment in this group of patients. So, keep in mind that prior to the study, the standard of care was carboplatin, or cisplatin with paclitaxel plus or minus bevacizumab, which yielded a median overall survival range in anywhere from 13 to 17 months depending on whether you use bevacizumab or not. And then adding pembrolizumab to that regimen, increase the median overall survival to 24 months, which is very promising. Dr. James Stuart Ferriss: If I remember correctly, KEYNOTE-826 allowed investigators choice, use of bevacizumab, and initially we were unsure about which regimen was best. Has there been additional data since? Dr. Jayanthi Lea: There has been additional data since. And another study that was done in the same vein was the BEATcc trial, which also looked at the different checkpoint inhibitors, atezolizumab in combination now with bevacizumab and platinum-based chemotherapy. And the control arm for this study was the GOG 240 regimen, which included bevacizumab. And this study showed both a progression-free and overall survival difference. The median overall survival in this study was 32 months with the incorporation of the checkpoint inhibitor to the bevacizumab and platinum-based chemotherapy. So, the way that I look at it is that the BEATcc trial basically confirmed the findings of KEYNOTE-826 and highlights that it is important for us to incorporate checkpoint inhibition with immunotherapy along with bevacizumab when we're treating patients with a recurrence. Dr. James Stuart Ferriss: Also, folks with primary advanced treatment for cervical cancer, this would be a great regimen, is that right? Dr. Jayanthi Lea: Absolutely. Primary advance, we would want to use the same regimen for that. Dr. James Stuart Ferriss: Okay. What about locally advanced in primary treatment? What advances have we seen? Dr. Jayanthi Lea: So we've had some major changes in that field as well, especially with the recent KEYNOTE-A18 data where pembrolizumab was administered in combination with external beam radiation and concurrent chemotherapy. And this study showed that there was significant and clinically meaningful improvement in progression-free survival compared to chemoradiation alone. Specifically, the progression-free survival at 24 months using pembrolizumab with chemoradiation was 68%, and 57% when in the placebo group. The hazard ratio for disease progression was 0.7 and no new safety signals were observed, which is fantastic, especially given the 0.7 hazard ratio that received PFS. Dr. James Stuart Ferriss: Yeah, absolutely. These patients with locally advanced cervical cancer often are quite symptomatic, and the prospect of adding chemo, radiation, and now immunotherapy on top of that is really encouraging to see that it was such a well-tolerated regimen. I believe that there were patient-reported outcomes recently reported at SGO. Dr. Jayanthi Lea: Absolutely. So, the safety profile of pembrolizumab and chemoradiation was consistent with the known profile of the individual treatment components. And no new safety signals emerged in the pembrolizumab chemoradiation arm. So, you're right. It was very well tolerated. Dr. James Stuart Ferriss: What would you say are the takeaways for folks who are seeing these patients in the community? These locally advanced cervical cancer patients that are now adding immunotherapy in a space that we have not used routinely in the past in terms of combining it with chemo radiation in gynecologic cancer. What are some things they should be looking out for? Dr. Jayanthi Lea: Well, I think that with the hazard ratio of 0.7 and the patient-reported outcomes showing no new signal, I think we can say that there is a positive benefit-to-risk profile of adding pembrolizumab in combination with chemoradiation, and that we should feel comfortable using this regimen. Now, of course, we have individualized patient care, and be able to know when to use bevacizumab, when to use immunotherapy. So, taking the whole patient into consideration becomes important. But for those individuals who are able to receive these drugs who don't have concrete issues to not receive these drugs [then I'd say we could] incorporate them since the safety profile is set. Dr. Linda Duska: I would add to that, Dr. Ferriss, that right now we only have FDA approval in the U.S. for stage 3-4A disease, and that's 2014 staging. Mind you, we are now in 2018, so we should be very careful in and follow the correct FIGO staging. But the FDA only gave approval for stage 3-4A disease, even though the study included patients with earlier stage disease and positive nodes. Dr. James Stuart Ferriss: That's a great point, thank you. So, Dr. Duska, thinking about endometrial cancer and advanced endometrial cancer, we have seen a similar revolution in the care of patients over the past few years, with major shifts in our approach. Can you remind us how we got here? Dr. Linda Duska: Yes, I would say in the ‘90s and before, and maybe even in the early 2000s, we used a lot of radiation for endometrial cancer as adjuvant therapy following surgery. The general consensus and what we were all taught was that this was a chemotherapy-resistant disease. And then we learned from a variety of GOG at the time, Gynecologic Oncology Group trials, that this disease is actually chemosensitive. And we went through a series of chemotherapy drugs, ranging from adriamycin cisplatin to taxel adriamycin cisplatin, and finally to taxel and carboplatin, demonstrating that this disease is actually quite chemosensitive. With this realization came the idea that maybe it would be important to combine chemotherapy and radiation particularly in high-risk endometrial cancer cases, so those with positive nodes or patients with high-risk histology such as clear cell or serous cancers. So two very important trials were done, one of them was PORTEC-3 and the other was GOG-258, which looked at combining chemo and radiation together to see if we could do better than one or the other alone. And they were very different trials, and they looked at different populations of patients and they looked at different things. For example, PORTEC-3 randomized patients to receive chemotherapy and radiation versus radiation alone, while 258 looked at chemotherapy and radiation versus chemotherapy alone. Without going into a great amount of detail, I think what we learned from both of those studies, and I think surprised many of us, that the arms that included chemotherapy, those patients did better. In fact, the results of GOG-258 can be interpreted – and this is somewhat controversial – but can be interpreted that many of these high-risk patients don't need radiation at all, or perhaps need tumor-directed radiation. For example, chemotherapy followed by tumor-directed radiation either to the vaginal cuff, because the vaginal cuff is at risk for recurrence, or perhaps to an area of concern, maybe the cervix if there were cervical involvement or if there is a particular concern for local recurrence in a particular patient. So, I think the pendulum has swung from almost always using radiation alone to, in more modern day, using chemotherapy and using radiation much more sparingly, and then comes immunotherapy. Dr. James Stuart Ferriss: So, update us on the results of NRG-GY018 and RUBY? Dr. Linda Duska: So, we've already talked about the KEYNOTE basket trials, which really contributed a lot to our understanding of the importance of MMR deficiency and microsatellite unstable disease. The KEYNOTE-158 study and the GARNET study showed us how important it was for women with MMRd and MSI endometrial cancer to receive checkpoint inhibition, and actually with remarkable response rates to women who had already been pretreated. But we also learned from the GARNET trial, which included MMRp patients, that the response rates in MMRp were not that great. And that led to KEYNOTE-775, which looked to combine pembrolizumab with a VEGF inhibitor, lenvantinib, to see if we could make the cold tumor hot. And indeed, we could. And not only could we improve the response rate in patients with MMRp tumors, but we could also improve the response rate in patients with MMRd tumors. They did better with the combination than they did with pembro alone. That led to the idea of combining checkpoint inhibitors with chemo upfront. The idea there was we were going to take paclitaxel and carboplatin, which were our backbone for advanced or recurrent endometrial cancer, and add immunotherapy to that. And to your point, GY018 and RUBY trials did just that. And they allowed MMRd and MMRp patients and combined paclitaxel and carboplatin, either with dostarlimab in the case of RUBY, or pembrolizumab in the case of GY018. These studies, both of which were reported and published in the New England Journal of Medicine last year, showed remarkable findings in the upfront setting and potentially in the curable setting. And the OS data for RUBY were presented at SGO this year and were remarkable for MMRd patients. In the whole population, in the whole group in RUBY, there was a 16.4-month improvement in overall survival with the addition of dostarlimab which is just huge. When you look at the MMRd group, I think Dr. Powell described the overall survival improvement as unprecedented. I believe that was the word that he used. Also, he called it very robust, with a hazard ratio of 0.32 for the group that got dostarlimab, and a median OS that was not reached. So really remarkable. In addition, in the MMRp group, there was a seven-month improvement in OS that was significant. So that's really amazing in the RUBY trial. It's also of note that the RUBY trial allowed carcinosarcomas, whereas the GY018 study did not. So, I think it's fair to say that these results apply to carcinosarcomas. It's also really important to note that many of the patients in the immunotherapy group who received placebo, 41% of them got IO in a later treatment line, and these OS data still stand. So that's really interesting and hypothesis-generating. For GY018, we don't have mature OS data yet, so we can't talk about OS. But we saw a similar improvement in PFS in both arms, in the d and the pMMR, with an OS trend in both arms that was also reported at SGO. GY018 was a little bit different though, because they unblinded at the time of the PFS reporting last year, and so those patients were unblinded a lot earlier than the RUBY patients were. So, to interpret the data in that vein, the OS data is not mature, but we anticipate looking at the PFS curves and the preliminary OS curves, that the OS data will also be statistically significantly improved in core pembrolizumab in GY018. What's also really interesting, and we haven't talked about molecular subtypes, is that when we look at the molecular subtypes in RUBY, and I'm sure we're going to see data on the molecular subtypes in GY018 coming up, different molecular subtypes of endometrial cancer respond differently to IO. And so, there's going to be lots of really interesting data coming our way soon that we're really excited to see, and that will help us triage patients appropriately into treatment regimens. Dr. James Stuart Ferriss: Dr. Lea, did you have a thought? Dr. Jayanthi Lea: Yeah, I just wanted to comment that looking at the dMMR survival curve in the file that was presented recently, one thing that really strikes me is the importance of adding the IO at the time of initial treatment. The separation of the curves persists. And, like you just mentioned, Dr. Duska, I mean, some of those patients who received placebo then later on went to get an IO treatment, but at the same time, we still see a vast separation of those curves. So, I think it's really important to note that immunotherapy should be used upfront, especially in dMMR. Dr. Linda Duska: Yeah, I completely agree with that. And I think that might be– I mean, this is just a hypothesis, but I think that that might be why we saw a difference with the addition of immunotherapy in the MMRp group, because it's possible that the chemotherapy created an immune environment that made the checkpoint inhibitor work more successfully than it would have otherwise. So, a really good point. You definitely need to include dostarlimab or pembrolizumab with the chemotherapy and then as maintenance therapy after. Dr. James Stuart Ferriss: So, you mentioned, we're increasingly thinking about endometrial cancer in smaller and smaller buckets of patients with very prescribed molecular profiles. We don't yet have enough information to specifically tailor treatment. How are you approaching that today in patients that you see in clinic? Dr. Linda Duska: Well, the MMR, and I'm interested in what you both are doing also, it's easy with the MMRd and MSI high patients. Those patients all should receive a checkpoint inhibitor, no question. The patients that are p53 mut, I test them for HER2, because we do have data to suggest that atezolizumab or TDX-d might be useful in those individuals, HER2 positive. And then the remaining patients, also called the NSMPs. That's a difficult group. I'm interested to know how you all manage them. I think that's the group where more clinical research is really needed to determine what the best treatment regimen for them is. But I'm interested in both of your thoughts on that. Dr. James Stuart Ferriss: Dr. Lea? Dr. Jayanthi Lea: I would have to say that I do exactly like you do, Dr. Duska. Dr. James Stuart Ferriss: And I would say our approach is very similar. And we have a robust discussion always about the use of immunotherapy with chemotherapy and in patients who are proficient MMR. But I think that most of us believe that the PFS data is certainly compelling. And now the OS data from RUBY, very compelling in both groups. And so, we are routinely recommending the use of immunotherapy along with chemotherapy in these advanced patients. Dr. Linda Duska: I've heard the argument made that GY018 required measurable disease, and so does not necessarily apply to patients without measurable disease. I'm not sure that I agree with that. I think there were clinical trial reasons why that was a requirement rather than biologic reasons. In addition, as we already discussed, RUBY included carcinosarcomas and GY018 did not. I don't think there's a reason to only use dostarlimab for carcinosarcomas, but that said, I don't know that pembrolizumab has an indication for carcinosarcomas. The devil's in the details, don't get too lost in the weeds. I think the take-home message here is that it's really important to use IO, particularly for the MMRd patients with endometrial cancer, upfront. And based on the OS that we saw in both RUBY and preliminarily in GY018, we may be curing some people with this regimen, and I think we should focus on that. The overall survival for advanced endometrial cancer is not great, and if we can improve that and potentially cure some people, that's a huge advance for our patients. Dr. James Stuart Ferriss: Do you envision a day that we might even ask the question, “Do we need to do surgery?” Dr. Linda Duska: So, the rectal data would support that assertion. I'm not sure that endometrial cancer and rectal cancer are the same thing. And I think that taking out a postmenopausal woman's uterus is a lot less morbid than potentially radiating or taking out somebody's rectum. I think a different question would be, is there a day when we would stop doing no dissection? We could definitely debate that, but I don't see that happening. Do you see that happening anytime soon? A stopping of hysterectomy for endometrial cancer? Dr. Jayanthi Lea: I don't see that happening anytime soon. And I think, as you said, taking out the uterus, tubes, and ovaries, it does provide us with some information about whether you're even dealing with a secondary primary. But also, it's from a quality-of-life standpoint. If a woman has a large uterus, that's uncomfortable. Postmenopausal bleeding, avoiding bleeding during the course of treatment, so many reasons why I wouldn't be in too much of a hurry to want to not do surgery for these patients. Dr. James Stuart Ferriss: So, we'll put a plug in for our fellow gynecologic oncologists that we still have a role to play in the incorporation of treatment regimens for patients with advanced uterine cancer. So it's not just medicine, there's still a role for surgery. Dr. Linda Duska: I think that's very fair, yeah. Dr. James Stuart Ferriss: Okay. I think that's all the time we have for today. I want to thank our listeners for their time, and you'll find the links to all the studies we've discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Thank you. Dr. Linda Duska: Thank you. Dr. Jayanthi Lea: Thank you. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care, and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers: Dr. James Stuart Ferriss Dr. Linda Duska @LDuska Dr. Jayanthi Lea Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. James Stuart Ferriss: Honoraria: National Board of Medical Examiners Dr. Linda Duska: Consulting or Advisory Role: Regeneron, Inovio Pharmaceuticals, Merck, Ellipses Pharma Researching Funding (Inst): GlaxoSmithKline, Millenium, Bristol-Myers Squibb, Aeterna Zentaris, Novartis, Abbvie, Tesaro, Cerulean Pharma, Aduro Biotech, Advaxis, Syndax, Pfizer, Merck, Genentech/Roche, Cerulean Pharma, Ludwig Institute for Cancer Research, Leap Therapeutics Patents, Royalties, Other Intellectual Property: UpToDate, Editor, British Journal of Ob/Gyn Dr. Jayanthi Lea: Consulting or Advisory Role: Roche
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CVY865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 17, 2025.Redefining Endometrial and Ovarian Carcinoma Care: Maximizing the Clinical Potential of Immunotherapy, ADCs, PARP Inhibitors, and Other Emerging Treatment Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, the Foundation for Women's Cancer, and the National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Eisai Inc., ImmunoGen, Inc., Karyopharm Therapeutics, and Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CVY865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 17, 2025.Redefining Endometrial and Ovarian Carcinoma Care: Maximizing the Clinical Potential of Immunotherapy, ADCs, PARP Inhibitors, and Other Emerging Treatment Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, the Foundation for Women's Cancer, and the National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Eisai Inc., ImmunoGen, Inc., Karyopharm Therapeutics, and Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CVY865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 17, 2025.Redefining Endometrial and Ovarian Carcinoma Care: Maximizing the Clinical Potential of Immunotherapy, ADCs, PARP Inhibitors, and Other Emerging Treatment Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, the Foundation for Women's Cancer, and the National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Eisai Inc., ImmunoGen, Inc., Karyopharm Therapeutics, and Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CVY865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 17, 2025.Redefining Endometrial and Ovarian Carcinoma Care: Maximizing the Clinical Potential of Immunotherapy, ADCs, PARP Inhibitors, and Other Emerging Treatment Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, the Foundation for Women's Cancer, and the National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Eisai Inc., ImmunoGen, Inc., Karyopharm Therapeutics, and Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Andrea Rosati. Mr. Rosati is a consultant at the Department of Gynecologic Oncology at Fondazione Policlinico Universitario Agostino Gemelli in Rome (Italy). He is currently attending a second level master "Gynecologic Oncology International Master" at the Catholic University of the Sacred Heart (Rome, Italy) accredited as a Subspecialty Fellowship by the European Society of Gynaecological Oncology. His main interest areas are gynecological cancer, surgical anatomy, and gynecologic oncology surgery. Highlights: This study evaluated the prevalence of concurrent endometrial cancer in patients with pre-operative diagnoses of atypical endometrial hyperplasia undergoing hysterectomy. Among 460 patients, 47.2% were found to have concurrent endometrial cancer. According to ESGO-ESTRO-ESP classification, 71.4%, were low-risk, 9.7% intermediate, 11.1% high to intermediate and 7.8% high-risk tumors. Positive Lymph node were found in 12 patients, accounting for the 7.6% of concurrent endometrial cancers who underwent SLN biopsy. SLN biopsy allowed for the adjustment of adjuvant therapy in 12.3% of high to intermediate-risk patients without increasing operative time or complication rates.
FertiliPod: Reproductive Medicine and Fertility podcast for professionals
Live IVIRMA Journal Club from January 18th. Dr. Haley Genovese presents an article by Baris Ata et al. recently published in Fertility & Sterility. Drs. Jason Franasiak and Emre Seli comment on the effect of the endometrial thickness on the live birth rate after a euploid frozen embryo transfer, followed by Q&A from the audience including Antonio Pellicer, Thomas Molinaro, Kassie Bollig, and Filippo Ubaldi. Podcast website: https://www.ivi-rmainnovation.com/fertilipod/
Dr. Harvey Kliman discovered and created the Endometrial Function Test. He is Director of the Reproductive and Placental Research Unit at Yale and focuses his research on infertility and pregnancy complications. In addition to his research and teaching activities at Yale, he also consults with Physicians to evaluate complicated cases related to pregnancy loss, and poor pregnancy outcomes. I'm honored to have him join me on The Egg Whisperer Show podcast to talk about the EFT, the endometrium, and everything you need to know about implantation. Read the article on Dr. Aimee's Website. Find Dr. Kliman online, here. Do you have questions about IVF? Join Dr. Aimee for The IVF Class at The Egg Whisperer School. The next live class call is on Monday, February 12, 2024 at 4pm PST, where Dr. Aimee will explain IVF and there will be time to ask her your questions live on Zoom. Subscribe to my YouTube channel for more fertility tips! Join Egg Whisperer School Checkout the podcast Subscribe to the newsletter to get updates Dr. Aimee Eyvazzadeh is one of America's most well known fertility doctors. Her success rate at baby-making is what gives future parents hope when all hope is lost. She pioneered the TUSHY Method and BALLS Method to decrease your time to pregnancy. Learn more about the TUSHY Method and find a wealth of fertility resources at www.draimee.org.
Endometrial-like tissue can grow anywhere throughout your body and can cause symptoms that may not seem connected to your Endometriosis or be acknowledged by medical specialists as a symptom. In this episode I discuss 3 less well-known symptoms and how they may be caused by your Endometriosis. If you have unusual symptoms and would like to have a chat about whether nutrition may help to reduce them, book an obligation-free 30-minute Endometriosis SOS Call. https://eatwelllivewell.com.au/endometriosis-sos-call/
Cervical Cancer … Compared to Endometrial Uterine Cancer (YouTube video # 340) What if you had to compare cervical cancer and endometrial uterine cancer? Could you? Your cervix is actually connected to … and a part of … your uterus. But does that mean the cancers of the two sites are similar? In this podcast tutorial, I'll begin our unit on cervical cancer by contrasting and comparing it to endometrial uterine cancer. Their differences and similarities might surprise you.
Menopause Management After Endometrial Uterine Cancer (YouTube video # 339) What if you've already had endometrial uterine cancer and you still need to manage your menopause? What options are available to you in that circumstance? Would there be certain options that are prohibited? Or would you be able to manage your menopause as you please? I'll tell you in this podcast.
Mechanical Options for Preventing Endometrial Uterine Cancer (YouTube video # 338) What if you needed or wanted to rely on a “mechanical” option for preventing endometrial uterine cancer? Would you know what's available to you? And would you know how those options differ in terms of the actual process of using them or their efficacy? In this podcast tutorial, I'll reach into my toolkit and show you all the mechanical options to bring you up to speed.
HRT Dosages for Preventing Endometrial Uterine Cancer (YouTube video # 337) If you decide to use HRT to prevent Endometrial Uterine Cancer, do you know the dosages of estrogen and progestogen to take? Do you know what dictates those dosages? Does it matter whether your goal is to just prevent endometrial uterine cancer versus prevent the diseases due to estrogen deficiency? This podcast tutorial will explain it all.
HRT Regimens for Preventing Endometrial Uterine Cancer (YouTube Video # 326) If you choose to use hormone replacement for preventing endometrial uterine cancer, you have to know about the different regimens for doing so. In this video tutorial, I'll make sure you do. This is an ultra-critical aspect of your management.
) Herbal Options for Preventing Endometrial Uterine Cancer (YouTube Video # 325) What if your preference is to use herbal options for preventing endometrial uterine cancer? Would you know which raw herbs to use? And would you know how to assess the herbs in the manufactured products you find on store shelves? A balance between estrogen and progesterone is the absolute most critical requirement for success. You'll need to listen to this podcast to ensure you understand how to accomplish that.
Exercise Options for Preventing Endometrial Uterine Cancer (YouTube Video # 324) One of the big risk factors for endometrial uterine cancer is being fat. And if you want to reduce that risk factor, you need to reduce your fat. One way to reduce fat is to exercise. But most women who are at risk of endometrial uterine cancer are fat because they are not in the habit of exercising. In this podcast tutorial, I'll give you 15 simple rules of exercise to keep it simple and succeed at cutting the fat.
Today on The Egg Whisperer Show podcast, I'm honored to be sharing a conversation all about endometrial analysis. Originally hosted by Tiffany Stankewicz and Nasser Al Asmar of Igenomix / Vitrolife Group, this interview included Dr. Allison Rodgers and Dr. Aimee We did a deep dive on how endometrial analysis works, and the tools that are available for fertility patients to get a better understanding of what may be happening with their endometrial lining. We also talk about how endometrial receptivity testing can lead to better outcomes for patients. The truth is that up to 30% of women have pathogenic bacteria in their endometrial lining that can negatively affect an embryo's ability to implant, and the good news is that there are simple antibiotics that can improve the lining. Dr. Rodgers and I have both had a lot of experience using the tools that Igenomix has created to test the endometrium, and we have both found that they can improve a patient's chance for a successful pregnancy. They call the trio of tests “Endometrio” and it includes EMMA, ALICE, and ERA. These three tests do the following: ERA (Endometrial Receptivity Analysis) - The ERA test evaluates the stage of an endometrium to determine if a receptive or non-receptive genetic profile is present at the time of biopsy. EMMA (Endometrial Microbiome Metagenomic Analysis) - A screening test to evaluate the endometrium at the microbiological level. ALICE (Analysis of Infectious Chronic Endometritis) - ALICE detects the bacteria causing chronic endometritis to improve your patient's reproductive prognosis. Tune in to learn more about endometrial analysis and how these tests, and the science behind them, can give fertility patients more insights about their endometrium, implantation, and chances for pregnancy. Thank you for hosting, Tiffany and Nasser, and thank you for the great discussion, Allison! You can tune in to all of the discussions hosted by Igenomix at ASRM on YouTube. Do you have questions about IVF? Click here to join Dr. Aimee for The IVF Class. The next live class call is on Monday, November 13th, 2023 at 4pm PST, where Dr. Aimee will explain Egg Freezing and there will be time to ask her your questions live on Zoom. Watch videos of Dr. Aimee answer Ask the Egg Whisperer Questions on YouTube. Sign up for The Egg Whisperer newsletter to get updates Dr. Aimee Eyvazzadeh is one of America's most well known fertility doctors. Her success rate at baby-making is what gives future parents hope when all hope is lost. She pioneered the TUSHY Method and BALLS Method to decrease your time to pregnancy. Learn more about the TUSHY Method and find a wealth of fertility resources at www.draimee.org.
Dr. Natalie Crawford discusses the fertility treatment add on called the ERA test or Endometrial Receptivity Analysis test. This test is used to look at the gene profile of the endometrium to see if it fits their definition of "perfect" implantation window timing. In this episode, Dr. Crawford reviews different studies of the ERA test and whether or not this test improves treatment outcomes. Natalie answers your fertility questions in FFS-For Fertility's Sake I had to stop my stimulation on day number 7 because of hyper stimulation. What should I do? I have my retrieval coming up and previously had two failed transfers. What are your suggestions to prepare for the cycle? Can having a D&C impact your chances of getting pregnant after? I'm not getting pregnant quickly like I did before. How often should we get our fertility testing done? Should we get yearly AMH and semen analysis done? We have moved Fertility In The News to the weekly newsletter in order to keep the podcast more evergreen. If you want to sign up go to nataliecrawfordmd.com/newsletter to sign up! Don't forget to ask your questions on Instagram for next week's For Fertility's Sake segment when you see the question box on Natalie's page @nataliecrawfordmd. You can also ask a question by calling in and leaving a voicemail. Call 657–229–3672 and ask your fertility question today! Thanks to our amazing sponsors! Check out these deals just for you: Factor- Head to factormeals.com/aaw50 and use code aaw50 to get 50% off. Apostrophe- Get your first visit for only five dollars at Apostrophe.com/AAW or use the code AAW at checkout. HoneyLove- Get 20% OFF by going to honeylove.com/aaw Beam-Go to youcanbeam.com and use code “AAW” for 10% off site wide If you haven't already, please rate, review, and follow the podcast to be notified of new episodes every Sunday. Plus, be sure to follow along on Instagram @nataliecrawfordmd, check out Natalie's YouTube channel Natalie Crawford MD, and if you're interested in becoming a patient, check out Fora Fertility. Learn more about your ad choices. Visit megaphone.fm/adchoices
Dr. Harvey Kliman discovered and created the Endometrial Function Test. He is Director of the Reproductive and Placental Research Unit at Yale and focuses his research on infertility and pregnancy complications. In addition to his research and teaching activities at Yale, he also consults with Physicians to evaluate complicated cases related to pregnancy loss, and poor pregnancy outcomes. I'm honored to have him join me on The Egg Whisperer Show podcast to talk about the EFT, the endometrium, and everything you need to know about implantation. Read the article on Dr. Aimee's Website. Find Dr. Kliman online, here. Do you have questions about IVF? Join Dr. Aimee for The IVF Class at The Egg Whisperer School. The next live class call is on Monday, September 25, 2023 at 4pm PST, where Dr. Aimee will explain IVF and there will be time to ask her your questions live on Zoom. Subscribe to my YouTube channel for more fertility tips! Join Egg Whisperer School Checkout the podcast Subscribe to the newsletter to get updates Dr. Aimee Eyvazzadeh is one of America's most well known fertility doctors. Her success rate at baby-making is what gives future parents hope when all hope is lost. She pioneered the TUSHY Method and BALLS Method to decrease your time to pregnancy. Learn more about the TUSHY Method and find a wealth of fertility resources at www.draimee.org.
We have decided to move Fertility In The News to the weekly newsletter in order to keep the podcast more evergreen. If you want to sign up go to nataliecrawfordmd.com/newsletter to sign up! Natalie answers your social media questions during her segment FFS—For Fertility's Sake. Can you get pregnant with one Fallopian tube? Is an ERA worth it? Can hypothyroidism impact my ability to have a baby? My luteal phase is 10 days but my progesterone levels are normal. Is this okay? Don't forget to ask your questions on Instagram for next week's For Fertility's Sake segment when you see the question box on Natalie's page @nataliecrawfordmd. You can also ask a question by calling in and leaving a voicemail. Call 657–229–3672 and ask your fertility question today! Thanks to our amazing sponsors! Check out these deals just for you: Apostrophe- Get your first visit for only five dollars at Apostrophe.com/AAW or use the code AAW at checkout. Cozy Earth - Up to 35% off site wide when you use the code AAW on cozyearth.com Before- 20% discount on their first order with code AsAWoman at checkout on BeforeCompany.com Liquid IV- Go to liquidiv.com and use code AAW at checkout for 20% off BetterHelp - Go to BetterHelp.com/AAW today to get 10% off your first month. Athena Club-Go to athenaclub.com and use code AAW for 25% off your first order. If you haven't already, please rate, review, and follow the podcast to be notified of new episodes every Sunday. Plus, be sure to follow along on Instagram @nataliecrawfordmd, check out Natalie's YouTube channel Natalie Crawford MD, and if you're interested in becoming a patient, check out Fora Fertility. Learn more about your ad choices. Visit megaphone.fm/adchoices
© 2020-2025 Ivy Podcast Discovery LLC
